Using FOTO Data and Peer Review to Optimize Patient Care Julie Collins, MA, OTR/L April 6, 2014.
TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE
description
Transcript of TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE
![Page 1: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/1.jpg)
TO THE EISENMENGER COMPLEX PATIENT: HOW DO
WE OPTIMIZE CARE
Maria Concepcion C. Sison, MD, FPPS, FPCCPediatric Cardiologist
![Page 2: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/2.jpg)
Eisenmenger Complex
Victor Eisenmenger (1897): 32 yo/male with cyanosis and dyspnea since infancy, was active until 3 years before death; succumbed to hemoptysis Autopsy: large malaligned VSD, marked RVH
Paul Wood (1951): described pathophysiology of Eisenmenger syndrome as PULMONARY HYPERTENSION with REVERSED SHUNT
![Page 3: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/3.jpg)
EISENMENGER Complex/Syndrome/Physiology: DEFINITION
Pulmonary vascular obstructive disease induced by uncorrected significant left-to-right shunt (any large congenital cardiac defect) causing a balanced or predominantly right to left shunt
![Page 4: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/4.jpg)
Eisenmenger Complex/Syndrome: DEFINITIONHemodynamically:– Elevation of PVR to 12 (10) Wood units– Pulmonary-to-systemic resistance ratio ≥ 1.0– No significant respone so vasoreactivity testing
EISENMENGER SYNDROME =INOPERABILITY =PROGRESSIVE HEART FAILURE = INEVITABLE PREMATURE DEATH
![Page 5: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/5.jpg)
Eisenmenger Complex/Syndrome: PROGNOSIS
• LONG SYMPTOM FREE PERIOD• USUALLY SYMPTOMATIC AROUND 30 years old• USUALLY DIE BETWEEN 30-35 years old• Actuarial survival rate:– 80% at 10 years– 77% at 15 years– 42% at 25 years
Kaemmerer H et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options. Current Cardiology Review 2010;6:343-355
![Page 6: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/6.jpg)
“LIGHT IN THE TUNNEL: OPTIMIZING CARE OF THE EISENMENGER
PATIENT”
![Page 7: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/7.jpg)
OUTLINE1. Definition of Eisenmenger Complex (EC)2. Pathophysiology relevant to management3. Problems and complications of EC4. Therapeutic Objectives5. Choose Optimal Therapy- efficacy, safety
a. “Standard or Conventional” Therapyb. “Advanced or New” Therapy
6. Other Issues/General Measures/Supportive Treatment
![Page 8: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/8.jpg)
PATHOPHYSIOLOGY
Beghetti M and Galie N. J Am Coll Cardiol 2009;53:733-740
![Page 9: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/9.jpg)
PATHOPHYSIOLOGYVASOACTIVE MEDIATORS PAH-CHDEndothelin-1 and endothelin receptors A and BAngiotensin II and angiotensin receptorsVascular endothelial growth factor and the flk1/tdr receptor
SIGNALING PATHWAYS PAH-CHDCalcium-dependent K+ channelsIncreased phosphodiesterase 5 activityDecreased nitric oxide synthase activityAngiopoietin 1TenascinDiminished function of BMPR1A, BMPR2
Landberg MJ. Clin Ches Med 2007;28:243-253
![Page 10: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/10.jpg)
PROBLEMS AND COMPLICATIONS
1. Dyspnea on exertion, easy fatigability, shortness of breath, tiredness
2. Edema and fluid retention3. Palpitations/Cardiac arrhythmia4. Syncopal episodes5. Erythrocytosis – increased blood viscosity and
intravascular “sludging”– CVA, Renal insufficiency, pulmonary
thromboembolism
![Page 11: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/11.jpg)
PROBLEMS AND COMPLICATIONS: MULTISYSTEM DISORDER
5. Fluid retention and elevated systemic venous pressure may alter hepatic function
7. Hyperuricemia and gout8. Bleeding tendencies/Coagulation disorders– hemoptysis
9. Sudden death
![Page 12: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/12.jpg)
THERAPEUTIC OBJECTIVES:
1. TO IMPROVE QUALITY OF LIFE2. TO IMPROVE, IF NOT RELIEVE, SYMPTOMS3. TO DECREASE, IF NOT PREVENT,
MORBIDITY/COMPLICATIONS4. TO OPTIMIZE FUNCTIONAL/ EXERCISE CAPACITY5. TO IMPROVE HEMODYNAMICS (decrease PAP,
increase oxygenation)6. TO DELAY DETERIORATION, AND PROLONG
SURVIVAL, IF POSSIBLE
![Page 13: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/13.jpg)
STANDARD/CONVENTIONAL THERAPY
DIGOXIN – supportive treatmentDIURETICS- supportive treatmentANTIARRHYTHYMICS- when appropriateANTICOAGULANTS- controversialO2 THERAPY- controversialIRON SUPPLEMENTATION- general measure
![Page 14: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/14.jpg)
ANTICOAGULATIONEFFICACY: – Prevalence of pulmonary artery thrombosis in ES ~
20%– Shown to reduce morbidity and mortality in
patients with IPAHSAFETY:– Thrombus formation and bleeding coexist in
patients with ES.– Risk of Fatal and life threatening and bleeding
complication particularly significant hemoptysis Oechslin E et al. Current Cardiology Review 2010;6:363-372Beghetti M and Galie N. J Am Coll Cardiol 2009;53:733-740
![Page 15: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/15.jpg)
ANTICOAGULATION
May be CONSIDERED as supportive treatment in patients with PA THROMBOSIS in the ABSENCE of significant hemoptysis
Oechslin E et al. Current Cardiology Review 2010;6:363-372
![Page 16: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/16.jpg)
OXYGEN THERAPYEFFICACY:• In PAH: extrapolated from RCTs in COPD patients• Subjective benefit in patients with intense hypoxemia, dyspnea at rest
and loss of vital capacity
RISK and SIDE EFFECTS:• desiccation of nasal mucosa, epistaxis, sleep disturbance• No impact of nocturnal oxygen therapy on exercise capacity, natural
history and survival of the patients within a follow up period of 2 years.
Can be considered in cases in which it produces a consistent increase in O2 saturation and reduces symptoms
Oechslin E et al. Current Cardiology Review 2010;6:363-372
![Page 17: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/17.jpg)
IRON SUPPLEMENTATIONBASIS:
– Erythrocytosis – Hyperviscosity syndrome occurs at lower Hb level in the presence of
iron deficiency anemia– Iron deficiency may cause headache, reduced exercise tolearnce,
restless leg syndrome
CONTROVERSY: – No studies on the role of iron store repletion in lowering the occurrence
of other organ system damage or thrombosis – In vitro study: iron deficiency has no impact on blood viscosity
Iron deficiency must be avoided in ES!Oechslin E et al. Current Cardiology Review 2010;6:363-372
![Page 18: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/18.jpg)
Conventional Pharmacologic Treatment
• Conventional pharmacological treatment, including digitalis, diuretics, antiarrhythmics, anticoagulants, iron supplementation, and oxygen therapy, may be used empirically, BUT does not seem to alter survival rate
![Page 19: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/19.jpg)
NEWER/ADVANCED/ TARGETED THERAPIES
• For stable patients: “noli-me-tangere” is still an option due to delicate balance of many variables
• INDICATED IN PATIENTS WITH REDUCED EXERCISE TOLERANCE, INCREASING CYANOSIS, OR INCREASING SIGNS OF HEART FAILURE– WHO FC III-IV
Siegrun M et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part II: Medical Treatment-Study Results. Current Cardiology Review 2010;6:356-362
![Page 20: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/20.jpg)
ADVANCED/NEWER THERAPY
Beghetti M and Galie N. J Am Coll Cardiol 2009;53:733-740
![Page 21: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/21.jpg)
ADVANCED/NEWER THERAPY: PULMONARY VASODILATORS
• ENDOTHELIN-1 RECEPTOR ANTAGONISTS (BOSENTAN)
• PHOSPHODIESTERASE-5 INHIBITORS (SILDENAFIL)- • PROSTACYCLIN and PROSTACYCLIN ANALOGS
(EPOPROSTENOL)
TO SOME EXTENT, DEMONSTRATED IMPROVEMENT IN EXERCISE CAPACITY, QUALITY OF LIFE, AND HEMODYNAMICS
Siegrun M et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part II: Medical Treatment-Study Results. Current Cardiology Review 2010;6:356-362
![Page 22: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/22.jpg)
ET-1 ANTAGONIST: BOSENTAN
BOSENTAN: BREATHE-5– First RCT Eisenmenger patients, 16 weeks– Significant improvement in hemodynamics and exercise
capacity (6 MWD) without compromising oxygen saturations
• Approved for use in PAH both in adults in children• Maintained up to 40 wks (open-label)– Initial persistent improvement, decline after 1 year,
reduction to baseline after 2 years (natural progression vs tachyphylaxis)
![Page 23: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/23.jpg)
PDE-5 Inhibitors- Sildenafil
• SUPER-1: large prospective multicenter blinded and controlled:IPAH: improved EC (6 MW test), FC, HD
• In ES: case reports, series, observational studies, few RCT placebo: Safe and improved symptoms, FC, Exercise Capacity (6MWD, Ex duration, pulmonary HD)
Tadalafil- observational study (ES)- benefits in O2 sat and mean FC
![Page 24: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/24.jpg)
PROSTACYCLIN ANALOG:EPOPROSTENOL
• LIMITED DATA ON EFFICACY AND SAFETY IN ES• Case series: improved O2 and 6 MWD, FC
• IPAH– RCT: improved exercise capacity, QOL, hemodynamics
• Side effects IV Administration: CVA, infection
TREPROSTNIL (SC, IV)- IPAH, CTD, CHD– benefits on EC, HD, clinical events– Side effects: high frequency of injection site pain
Iloprost (inhalation)- IPAH Beraprost- no crucial role
![Page 25: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/25.jpg)
OPTIMIZING CARE IN ES
OTHER GENERAL MEASURES AND SUPPORTIVE TREATMENT
![Page 26: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/26.jpg)
PHLEBOTOMY
Phlebotomy with isovolumic replacement should be considered in the presence of moderate to severe symptoms of hyperviscosity
Prophylactic phlebotomy plays no role in patient management• Causes iron deficiency anemia, reduces exercise
tolerance
![Page 27: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/27.jpg)
HYPERVISCOSITY SYMPTOMS
![Page 28: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/28.jpg)
HYPERURICEMIA/GOUT
• Asymptomatic, secondary hyperuricemia is no indication for routine therapy to lower uric acid level because it does not have any serious impact on renal function
TREAT: Acute Gouty Arthritis
![Page 29: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/29.jpg)
ISCHEMIC EVENTS: REDUCING RISKS
• Avoidance and treatment of volume depletion;
• Iron supplementation in patients with iron deficiency or those undergoing repeated phlebotomies;
• Use of air filters in all intravenous lines.
Oechslin E et al. Current Cardiology Review 2010;6:363-372
![Page 30: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/30.jpg)
FACTORS THAT MAY AGGRAVATE PAH IN EISENMENGER SYNDROME
• PREGNANCY• Dehydration or acute
vasodilation (eg, sauna, hot tub)
• Increased fluid volume• Worsened renal or hepatic
function• Chronic environmental hypoxia• Increased left-sided filling
pressure• Left ventricular diastolic
dysfunction
• Obstructive congenital lesion
• Myocardial restriction• Systemic hypertension with
increased left ventricular afterload
• Erythrocytosis and increased blood viscosity; anemia
• Hypercoagulability: thrombosis
![Page 31: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/31.jpg)
OTHER GENERAL MEASURES
• Infective Endocarditis PROPHYLAXIS• Pregnancy and Contraception– ES is an absolute contraindication to Pregnancy– Maternal mortality= 30-60%– Spontaneous abortion=40%– Premature delivery 50%– IUGR 30% of infants– Perinatal infant mortality 8-28%
![Page 32: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/32.jpg)
Transplantation
• Heart/Lung Transplantation or Lung Transplantation with repair of CHD
• Option for patients with poor prognosis and poor quality of life
![Page 33: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/33.jpg)
SURVIVAL BENEFITS
• RETROSPECTIVE STUDY (systematic cohort), EISENMENGER PATIENTS RECEIVING ADVANCED THERAPY (Bosentan, Sildenafil, Epoprostenol) showed LOWER RISK OF DEATH
• 52 PATIENTS DIED, ONLY 2 WHILE ON AT
• CLINICAL DIFFERENCES STATISICALLY CORRECTED– Those on AT had more advanced disease
Dimopoulos K et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy For Pulmonary Arterial Hypertension. Circulation. 2010;121:20-25
![Page 34: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/34.jpg)
Management algorithm for PAH in CHD
Kaemmerer H et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options. Current Cardiology Review 2010;6:343-355
![Page 35: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/35.jpg)
“Teach us to number our days aright, that we may gain a heart of wisdom”
Psalm 90:12
![Page 36: TO THE EISENMENGER COMPLEX PATIENT: HOW DO WE OPTIMIZE CARE](https://reader036.fdocuments.us/reader036/viewer/2022062501/568165b5550346895dd8b241/html5/thumbnails/36.jpg)
MAJOR REFERENCES:• Kaemmerer H et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update
After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options. Current Cardiology Review 2010;6:343-355
• Siegrun M et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part II: Medical Treatment-Study Results. Current Cardiology Review 2010;6:356-362
• Oechslin E et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part III. Specific Management and Surgical Aspects. Current Cardiology Review 2010;6:363-372
• Dimopoulos K et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy For Pulmonary Arterial Hypertension. Circulation. 2010;121:20-25
• Landberg MJ. Congenital Heart Disease Associated Pulmonary Arterial Hypertension. Clin Ches Med 2007;28:243-253
• Beghetti M and Galie N. Eisenmenger Syndrome: A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2009;53:733-740